Cerca
Edicola digitale
+

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

default_image

AdnKronos
  • a
  • a
  • a

Dai blog